

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01. Amended 01/01/11.

Name of entity	CLINUVEL PHARMACEUTICALS LTD
ABN	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philippe Wolgen
Date of last notice	01 June 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest (Ordinary Shares)
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	30 June 2021
No. of securities held prior to change	3,297,996 Ordinary Shares (includes 2,199,810 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust and the Performance Rights Plan Trust) 1,513,750 Unlisted Performance Rights (various milestones, expiry date 20/11/2023)
Class	Ordinary Shares
Number acquired	Nil
Number disposed	122,675

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$3,748,582.55
No. of securities held after change	3,175,321 Ordinary Shares (includes 2,199,810 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust and the Performance Rights Plan Trust) 1,513,750 Unlisted Performance Rights (various milestones, expiry date 20/11/2023)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market sale, representing 3.71% of his holdings. The disposal of shares is to meet personal commitments and annual rebalancing of portfolio. Dr Wolgen does not receive annual fixed equity awards or options as part of his remuneration but is eligible to exercise Performance Rights conditional on meeting certain specified corporate Performance Conditions, within a 4-year vesting period, attached to the Performance Rights.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a